Defining immune-active mechanisms of PDL1V in translational ADC development

Key Points

• The research aims to define the immune-active mechanisms of PDL1V in advancing antibody-drug conjugate (ADC) development.
• Evaluated antitumor activity of PDL1V at multiple nonclinical doses.
• Characterized functional activation and trafficking of PD-L1-positive immune cells.
• Explored immune profiling techniques for deeper insights.
• Revealed synergistic antitumor activity across different nonclinical doses.
• Demonstrated effective activation and movement of cytotoxic immune cells.
• Suggested a broad therapeutic window for PDL1V application.